Physiolution GmbH is a highly innovative company focused on investigations of the dissolution behavior of solid oral dosage forms under bio-relevant test conditions. This will significantly strengthen DDIC’s capabilities in the development of modern formulation technologies. Their cutting-edge test methods, which will also be available in the new DDIC facilities, are based on many years of experience in the fields of gastro-intestinal tract physiology and biopharmaceutical evaluation of dosage form performance. In addition, the analytical services of Physiolution GmbH include pharmacopoeial dissolution testing and other pharmacopoeial investigations of solid oral dosage forms and their mechanical stability as well as development and validation of analytical methods and procedures, biochemical characterization of biomolecules and formulation of peptide drugs. For more information, please refer to this link.

The DDIC was founded in 2017 by the companies Bayer AG, LB Bohle GmbH, Merck KGaA (all Germany) and UCB S.A (Belgium), together with the university partners TU Dortmund and HHU Düsseldorf. INVITE GmbH is leading the consortium. The DDIC fosters international, multi-disciplinary networks in the research area of drug delivery and manufacturing, it promotes pharmaceutical science in close collaboration with academia and pharmaceutical industry along the value chain.